• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alaris

BD to pay SEC $175M to settle Alaris investigation

December 17, 2024 By Sean Whooley

BD Alaris Infusion System updated FDA clearance

BD (NYSE:BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system. The investigation relates to prior public disclosures and SEC reporting regarding Alaris, an infusion pump system. BD neither admits nor denies the findings of an SEC order related to those matters occurring more than four years […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Regulatory/Compliance Tagged With: Alaris, BD

FDA clears updated BD Alaris infusion system after long-term commercial hold

July 21, 2023 By Sean Whooley

BD Alaris Infusion System updated FDA clearance

BD (NYSE:BDX) announced today that the FDA granted 510(k) clearance for its updated Alaris infusion system. Shares of BDX closed out Friday evening priced at $264.84 each. They ticked up significantly after market close on the back of the Alaris news, rising 5.9% to $280.40 apiece. Clearance enables both remediation and a return to full […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: Alaris, BD, FDA

BD discloses 8 cybersecurity vulnerabilities with Alaris infusion system

July 13, 2023 By Sean Whooley

BD Alaris with Guardrails Suite MX

BD (NYSE:BDX) today voluntarily posted a product security bulletin for a number of vulnerabilities with its Alaris infusion system. Franklin Lakes, New Jersey-based BD recently identified eight vulnerabilities. These vulnerabilities are associated with the BD Alaris system with Guardrails Suite MX, versions 12.1.3 and earlier. The company discovered the vulnerabilities through routine internal security testing […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance, Technology Tagged With: Alaris, BD, Cybersecurity

BD issues vulnerability warning for Alaris infusion monitoring software

February 16, 2023 By Sean Whooley

BD Alaris Infusion Central software

BD (NYSE:BDX) today issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. Alaris Infusion Central, a standalone software — separate from pumps — provides data from the Alaris pumps. It allows healthcare providers to monitor infusion data sent from Alaris Plus and Alaris neXus pumps on a computer. Alaris Infusion Central […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Recalls, Regulatory/Compliance Tagged With: Alaris, BD

BD begins remediation in Alaris infusion system software recall

July 29, 2021 By Sean Whooley

BD Alaris infusion pump

BD (NYSE:BDX) announced today that it will begin remediation for a 2020 Class I-level recall of its Alaris infusion system. Franklin Lakes, N.J.–based BD has had shipments of Alaris pumps on hold after the FDA called for a comprehensive 510(k) submission to cover a host of software fixes, with pumps only going to health providers […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA) Tagged With: Alaris, BD, FDA

BD’s Alaris pump hit with another serious recall

April 30, 2021 By Nancy Crotti

BD Alaris infusion pump

A medical supply company is recalling BD (NYSE:BDX) Alaris infusion pumps — the third Class I recall for the pumps in recent months, according to the FDA. North Carolina-based Avante Health Solutions issued the Alaris pump recall March 24, 2021, because the bezel repair posts may crack or separate, leading to the inaccurate delivery of […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls Tagged With: Alaris, Avante Health Solutions, BD, FDA, Tenacore

Pump problem prompts another Alaris recall

April 19, 2021 By Sean Whooley

Tenacore

Days after classifying one recall for the Alaris infusion pump, the FDA has issued another Class I recall for the device. On Friday of last week, the FDA issued a Class I recall — the most serious kind — for the BD (NYSE:BDX) Alaris because there is a risk of the keypad lifting up due to […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: Alaris, BD, Tenacore

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS